

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications

Protocol summary

Study aim

To determine the effect of intratracheal injection of processed autologous serum derived from patients with COVID-19 in oxygenation parameters and pulmonary complications

Design

Randomised, superiority, parallel group, phase 2, single-center trial with blinded outcome assessment. Randomisation will be performed using block randomisation (n=4).

Settings and conduct

This study will be conducted in a 22-bed ICU in northwest of Iran. Intubated patients with COVID-19 under mechanical ventilation will be enrolled. The patients will receive all the standard treatments. Also, the blood sample of patients will undergo centrifugation with 5000/min for separating plasma and then will be incubated for 8 hours. Thereafter, the plasma will be injected intratracheally for patients. For patients in control group, normal saline serum in the same volume will be intratracheally administered. This procedure will be performed every 3 days and the maximum number of administration will be 3 times in both groups. Patients and their next of kin as well as the researcher who will assess the outcomes will be blind to the study.

Participants/Inclusion and exclusion criteria

Inclusion criteria: intubated COVID19 patients Exclusion criteria: transplantation history, malignancy, thoracic surgery, autoimmune disease and active bacterial infection

Intervention groups

In intervention group, the blood sample of patients will undergo centrifugation with 5000/min and then plasma will be incubated for 8 hours and injected intratracheally for patients. For control group, normal saline in the same volume will be intratracheally administered. This procedure will be performed every 3 days and the

maximum number of administration will be 3 times in both groups.

Main outcome variables

Primary outcome: change in oxygenation Secondary outcomes: change in CO₂; change in respiratory compliance; change in airway resistance

General information

Reason for update

Acronym

-

IRCT registration information

IRCT registration number: **IRCT20091012002582N21**

Registration date: **2020-05-18, 1399/02/29**

Registration timing: **retrospective**

Last update: **2020-05-18, 1399/02/29**

Update count: **0**

Registration date

2020-05-18, 1399/02/29

Registrant information

Name

Ata Mahmoodpoor

Name of organization / entity

Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 914 116 0888

Email address

mahmoodpoora@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-05-05, 1398/02/15
Expected recruitment end date
2019-08-06, 1398/05/15
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications

Public title
Effect of intrapulmonary injection of processed serum derived from covid-19 patients in reduction of pulmonary complications

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
intubated covid-19 patients
Exclusion criteria:
transplantation history malignancy thoracic surgery active bacterial infection autoimmune disease

Age
From **18 years** old to **70 years** old

Gender
Both

Phase
2

Groups that have been masked

- Participant
- Outcome assessor

Sample size
Target sample size: **30**

Randomization (investigator's opinion)
Randomized

Randomization description
Initially, the blocks (n=4) with different arrangements of A and B will be defined. Considering the different probable arrangement of A and B, blocks will be numbered from 1 to 6. To enroll initial 4 patients into the study, one of the arrangements will be selected using the random digit table and the patients will be assigned into the A and B groups accordingly. For the next 4 patients, the arrangement pattern will be selected again and the patients will be assigned to the groups and this cycle will be repeated to achieve our intended sample size. Unpredictability of assignment and balancing the number of patients across the two groups during or at the end of the study are main advantages of this method. Notably, the patients will be assigned into the study based on the ICU date of admission and no body will be able to assign the patients to the specific group of interest.

Blinding (investigator's opinion)
Double blinded

Blinding description
The aim of double blinding is the avoidance of patients

and researchers from being informed about the study intervention, so enrollment of patients in intervention and placebo groups will not be recognized. As the patients will be unconscious and under mechanical ventilation, they actually will not be aware of the group in which they are (intervention /placebo). The informed consent will be obtained from the patient's next of kin and they will thoroughly be informed about the study but they will be blind about the group in which their patient will be included. Also, the researcher who will assess the outcomes will not have any information about study enrollment and only primary investigator will know that. So, blinding will be performed for the researcher who will assess the study outcomes. As he/she will not be a member of treatment team and will be blinded to the study groups.

Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Tabriz University of Medical Sciences
Street address
General ICU, Imam Reza Hospital, Daneshkade Street
City
Tabriz
Province
East Azarbaijan
Postal code
5166614756
Approval date
2020-04-06, 1399/01/18
Ethics committee reference number
IR.TBZMED.REC.1399.014

Health conditions studied

1

Description of health condition studied
COVID-19
ICD-10 code
U07.1
ICD-10 code description
COVID-19, virus identified

Primary outcomes

1

Description

Oxygenation

Timepoint

During 10 days from intratracheal injection

Method of measurement

Arterial blood gas analysis

Secondary outcomes

1

Description

Change in CO₂

Timepoint

During 10 days after intratracheal intubation

Method of measurement

Analysis of arterial blood gases

2

Description

Respiratory compliance

Timepoint

During 10 days after intratracheal intubation

Method of measurement

Ventilator

3

Description

Airway resistance

Timepoint

During 10 days after intratracheal intubation

Method of measurement

Ventilator

Intervention groups

1

Description

Intervention group: After taking blood samples and centrifugation with 5000/min the plasma will be separated and incubated for 8 hours and then this plasma will be injected intratracheally for the patient. This procedure will be performed every 3 days and the maximum number of administration will be 3 times.

Category

Treatment - Drugs

2

Description

Control group: in the same volume for the patients in control group normal saline is intratracheally will be injected. This procedure will be performed every 3 days and the maximum number of administration will be 3 times.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

ICU General, Imam Reza Hospital

Full name of responsible person

Ata Mahmoodpoor

Street address

Imam Reza Hospital, Daneshkade street

City

Tabriz

Province

East Azarbaijan

Postal code

5166614756

Phone

+98 41 3335 2073

Fax

+98 41 3335 2073

Email

amahmoodpoor@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Khosro Adibkia

Street address

Daneshkade street

City

Tabriz

Province

East Azarbaijan

Postal code

5165665931

Phone

+98 41 3335 7310

Email

adibkia@tbzmed.ac.ir

Grant name

non

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Leila Roshangar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Histology

Street address

Faculty of Medicine, Daneshkade Street

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3334 2086

Fax

+98 41 3334 2086

Email

lroshangar@yahoo.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Ata Mahmoodpoor

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Anesthesiology

Street address

Imam Reza Hospital, Daneshkade street

City

Tabriz

Province

East Azarbaijan

Postal code

5166614756

Phone

+98 41 3335 2073

Email

amahmoodpoor@yahoo.com

Person responsible for updating data**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Leila Roshangar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Histology

Street address

Faculty of Medicine, Daneshkade Street

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

0098 41 3342086

Email

lroshangar@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Will be available if needed

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available